Analyst Downgrades Sequenom; New Benefits Provider Covering MaterniT21 Plus | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray today downgraded Sequenom's shares, citing increasing competition, as well as pricing pressures and legal concerns.

Separately, after the close of the market on Thursday, Sequenom said that its subsidiary, Sequenom Laboratories, has signed a national agreement with an unnamed "leading benefits provider" to provide coverage for the MaterniT21 Plus fetal aneuploidy test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.